{"id":379592,"date":"2020-11-12T08:03:45","date_gmt":"2020-11-12T13:03:45","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=379592"},"modified":"2020-11-12T08:03:45","modified_gmt":"2020-11-12T13:03:45","slug":"alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/","title":{"rendered":"Alimera Sciences Announces Real-World  Clinical Data for ILUVIEN\u00ae to be Presented at the  American Academy of Ophthalmology 2020 Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>ATLANTA, Nov.  12, 2020  (GLOBE NEWSWIRE) &#8212; Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that new real-world clinical data for ILUVIEN<sup>\u00ae<\/sup>\u00a0will be featured in 3 posters at the American Academy of Ophthalmology 2020 Virtual Conference. The posters will be available to registered attendees beginning Friday, November 13, 2020.<\/p>\n<p>Posters include:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">Abstract # 30064808: \u201cOutcomes from the prospective IDEAL registry study \u2013 results achieved with the 0.2 \u00b5g\/day fluocinolone acetonide implant\u201d \u2013 Khoramnia, et. al.\n<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">Abstract # 30064802: \u201cThree-year real-world outcomes from the IRISS registry study, using the 0.2 \u00b5g\/day fluocinolone acetonide (FAc) implant\u201d \u2013 Khoramnia, et. al.\n<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">Abstract # 30065140: \u201cPredictive value IOP challenge and other safety measures of PALADIN 2yr. data\u201d \u2013 Malik, et. al.<\/li>\n<\/ul>\n<p>\u201cILUVIEN is a uniquely durable therapy, providing physicians the opportunity to reduce the recurrence of diabetic macular edema, and therefore reduce the need for frequent injections of the current standard of care,\u201d\u00a0said Rick Eiswirth, President and CEO of Alimera.\u201cWe are very excited to have these abstracts showcased at the American Academy of Ophthalmology, highlighting the longer term three-year outcomes that support ILUVIEN\u2019s ability to give more DME patients the potential to see better, longer, with fewer injections.\u201d<\/p>\n<p>Registration to the conference can be accessed <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jveT6HCDkDWSVa4_lS-b813_QGF-diUbaCclLt4PUYpQ-vhi4H-X4Plju9WPFpaaOwjVGn9ByE8antRtMmYZJUzY_-Qi_0FiCqQD6VMBD_2T95cDiHQfJpaY9JxmKab5\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a>.<\/p>\n<p>\n        <strong>A<\/strong><br \/>\n        <strong>bout ILUVIEN<\/strong>\n      <\/p>\n<p>ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant, injected into the back of the eye. With its CONTINUOUS MICRODOSING\u2122 technology, ILUVIEN is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months, to reduce the recurrence of disease. ILUVIEN enables patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S., Australia, Canada, Kuwait, Lebanon and the U.A.E. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. ILUVIEN is indicated in 17 European countries for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies and in 16 European countries for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU). Alimera does not have the contractual right to pursue approval to treat uveitis in the U.S., and therefore does not have a regulatory license in the U.S. to treat NIPU. For important safety information on ILUVIEN, see <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DTMogzFHsbSa6wQO0zm4mFLV33XgXrvHX590It1up5ltsoO2U2ns9nBBqbDLO1Fg4nTLAha0XMSFNbHc-OfsNU67aEzPa6_J-aBJBmi5Rzo=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/iluvien.com\/#isi<\/a><\/p>\n<p>\n        <strong>About Alimera Sciences, Inc.<\/strong>\n      <\/p>\n<p>Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uabDKSC9dKcgsJfa-4mdGzS8V80hJfVBEVEYtfHmxQeLxyS_TEalB5_5GVomiMweaFxfP4-Y_I2I_kkZByftlINar4fOVsGWneTBXlsFfYE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.alimerasciences.com.<\/a><\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains \u201cforward-looking statements,\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera\u2019s beleif that ILUVIEN reduces the need for frequent injections of the current standard of care. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors include but are not limited to the willingness of physicians to consider ILUVIEN as an alternative to the current standard of care, as well as the factors discussed in the \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of Alimera\u2019s Annual Report on Form 10-K for the year ended\u00a0December 31, 2019 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020, and September 30, 2020 which are on file with the\u00a0Securities and Exchange Commission\u00a0(SEC) and available on the\u00a0SEC\u2019s\u00a0website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aC9RbuHHYKG3I3wglTEdS6ItAPqNXyPf1bEaC54u7bT93HdO52Lb7BZ62YftxcyPpfp7TGomb2_9HrxZRVk7fw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.sec.gov<\/a>.<\/p>\n<p>All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>For press inquiries:<\/strong><br \/>\n            <br \/>Jules Abraham<br \/>for Alimera Sciences <br \/>917-885-7378<br \/>julesa@coreir.com<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 30.0px;vertical-align: top\">\n            <strong>For investor inquiries:<\/strong><br \/>\n            <br \/>Scott Gordon<br \/>for Alimera Sciences<br \/>scottg@coreir.com<\/td>\n<\/tr>\n<\/table>\n<p>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p align=\"center\">\n        \n      <\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDQ0OSMzODIyODE1IzIwMDQwMTM=\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATLANTA, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that new real-world clinical data for ILUVIEN\u00ae\u00a0will be featured in 3 posters at the American Academy of Ophthalmology 2020 Virtual Conference. The posters will be available to registered attendees beginning Friday, November 13, 2020. Posters include: Abstract # 30064808: \u201cOutcomes from the prospective IDEAL registry study \u2013 results achieved with the 0.2 \u00b5g\/day fluocinolone acetonide implant\u201d \u2013 Khoramnia, et. al. Abstract # 30064802: \u201cThree-year real-world outcomes from the IRISS registry study, using the 0.2 \u00b5g\/day fluocinolone acetonide (FAc) implant\u201d \u2013 Khoramnia, et. al. Abstract # 30065140: \u201cPredictive value &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alimera Sciences Announces Real-World  Clinical Data for ILUVIEN\u00ae to be Presented at the  American Academy of Ophthalmology 2020 Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-379592","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alimera Sciences Announces Real-World Clinical Data for ILUVIEN\u00ae to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alimera Sciences Announces Real-World Clinical Data for ILUVIEN\u00ae to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that new real-world clinical data for ILUVIEN\u00ae\u00a0will be featured in 3 posters at the American Academy of Ophthalmology 2020 Virtual Conference. The posters will be available to registered attendees beginning Friday, November 13, 2020. Posters include: Abstract # 30064808: \u201cOutcomes from the prospective IDEAL registry study \u2013 results achieved with the 0.2 \u00b5g\/day fluocinolone acetonide implant\u201d \u2013 Khoramnia, et. al. Abstract # 30064802: \u201cThree-year real-world outcomes from the IRISS registry study, using the 0.2 \u00b5g\/day fluocinolone acetonide (FAc) implant\u201d \u2013 Khoramnia, et. al. Abstract # 30065140: \u201cPredictive value &hellip; Continue reading &quot;Alimera Sciences Announces Real-World Clinical Data for ILUVIEN\u00ae to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T13:03:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDQ0OSMzODIyODE1IzIwMDQwMTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alimera Sciences Announces Real-World Clinical Data for ILUVIEN\u00ae to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference\",\"datePublished\":\"2020-11-12T13:03:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\\\/\"},\"wordCount\":764,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDQ0OSMzODIyODE1IzIwMDQwMTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\\\/\",\"name\":\"Alimera Sciences Announces Real-World Clinical Data for ILUVIEN\u00ae to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDQ0OSMzODIyODE1IzIwMDQwMTM=\",\"datePublished\":\"2020-11-12T13:03:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDQ0OSMzODIyODE1IzIwMDQwMTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDQ0OSMzODIyODE1IzIwMDQwMTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alimera Sciences Announces Real-World Clinical Data for ILUVIEN\u00ae to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alimera Sciences Announces Real-World Clinical Data for ILUVIEN\u00ae to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Alimera Sciences Announces Real-World Clinical Data for ILUVIEN\u00ae to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference - Market Newsdesk","og_description":"ATLANTA, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that new real-world clinical data for ILUVIEN\u00ae\u00a0will be featured in 3 posters at the American Academy of Ophthalmology 2020 Virtual Conference. The posters will be available to registered attendees beginning Friday, November 13, 2020. Posters include: Abstract # 30064808: \u201cOutcomes from the prospective IDEAL registry study \u2013 results achieved with the 0.2 \u00b5g\/day fluocinolone acetonide implant\u201d \u2013 Khoramnia, et. al. Abstract # 30064802: \u201cThree-year real-world outcomes from the IRISS registry study, using the 0.2 \u00b5g\/day fluocinolone acetonide (FAc) implant\u201d \u2013 Khoramnia, et. al. Abstract # 30065140: \u201cPredictive value &hellip; Continue reading \"Alimera Sciences Announces Real-World Clinical Data for ILUVIEN\u00ae to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-12T13:03:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDQ0OSMzODIyODE1IzIwMDQwMTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alimera Sciences Announces Real-World Clinical Data for ILUVIEN\u00ae to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference","datePublished":"2020-11-12T13:03:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/"},"wordCount":764,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDQ0OSMzODIyODE1IzIwMDQwMTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/","name":"Alimera Sciences Announces Real-World Clinical Data for ILUVIEN\u00ae to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDQ0OSMzODIyODE1IzIwMDQwMTM=","datePublished":"2020-11-12T13:03:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDQ0OSMzODIyODE1IzIwMDQwMTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDQ0OSMzODIyODE1IzIwMDQwMTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alimera-sciences-announces-real-world-clinical-data-for-iluvien-to-be-presented-at-the-american-academy-of-ophthalmology-2020-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alimera Sciences Announces Real-World Clinical Data for ILUVIEN\u00ae to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=379592"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379592\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=379592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=379592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=379592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}